Intelligence Foundation

Built on verified data — not opinion.

The advisory edge starts here. Every term we anchor, every counterparty we propose, every valuation we sanity-check sits on the same proprietary intelligence foundation — refreshed daily, sourced from primary filings, and refined through every mandate.

Deal Volume by Therapeutic Area

Proprietary dataset · 2017–2026 · n = 2,500+

Oncology
875
Immunology
350
Neurology / CNS
275
Rare Disease
250
Metabolic
200
Cardiovascular
150
Hematology
125
Infectious Disease
100
Ophthalmology
75
Dermatology
50
Gastroenterology
40
Women’s Health
10
2,500+Deal Database
850+Companies Tracked
12Therapeutic Areas

Platform Ecosystem

Four products. One intelligence layer.

Each platform serves standalone revenue and a conversion funnel into advisory mandates.

Solidus

Live
solidus.ambrosiaventures.co

Deal benchmarking with paid reports and Pro subscriptions. The global on-ramp for operating companies.

Terrain

Coming Soon

Market intelligence for BD teams and investors. Individual, team, and enterprise access.

Investor Intelligence

In Development

Sourcing, fund-level benchmarking, LP-grade reporting, portfolio attribution.

IP Map

In Development

Patent intelligence and IP-driven valuation augmentation.

Four platforms. One intelligence layer — powering every advisory mandate with live, verified data.

Strategic Shape Diagnostic

True Platforms receive 2.3x the median upfront.

Most founders don’t know their shape — and the misclassification costs real money.

Every life sciences company preparing for a transaction has a strategic shape. The Shape Diagnostic classifies yours into one of seven archetypes using a scoring engine calibrated against 2,500+ verified transactions — then surfaces the contradictions between your stated identity and what the market evidence actually shows.

Your shape determines which deal structures apply — licensing in or out, M&A on either side, strategic partnerships — which counterparties engage, and what economics to expect. Getting it wrong means running the wrong process with the wrong partners at the wrong valuation.

$49

Full report

Seven minutes. Free classification.

Contradictions, comparable transactions, counterparty map, and a ready-to-use company description paragraph.

Take the Diagnostic

Sample Classification

ALPA

Asset-Led, Platform Aspiration

Confidence: Moderate · 14 points from TP

Contradiction

Capital plan is structured for a single asset, but company describes itself as a platform.

Contradiction

No counterparty has paid to validate the platform beyond the lead program.

Counterfactual

If classified as TP, comparable companies received $310M vs $134Mmedian upfront — a 2.3x difference.

7 Archetypes

SAALPATPETTRICSL

Bring us your transaction.

We’ll meet you at peer level — anywhere in the world.

Issa Kildani

Managing Partner

info@ambrosiaventures.co